Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
News|Articles|August 15, 2016
Mallinckrodt to Merge with Stratatech Corporation
Author(s)Pharmaceutical Technology Editors
Mallinckrodt announced a planned merger agreement with Stratatech Corporation, a regenerative medicine company.
Advertisement
On August 10, 2016, Mallinckrodt announced that it has entered into a merger agreement with Stratatech Corporation, a privately held regenerative medicine company focused on the development of proprietary skin substitute products. Some developmental products include StrataGraft regenerative skin tissues and a platform for genetically enhanced skin tissues, Mallinckrodt said in a press announcement. The financial terms of the agreement were not disclosed, and Mallinckrodt anticipates the transaction will close in the second half of calendar 2016.
Stratatech Corporation is currently working on development of StrataGraft, which if approved, would be an off-the-shelf skin substitute product for the treatment of severe burns. StrataGraft is designed to produce living tissues that mimic human skin and promote tissue regeneration. The technology platform provides potential for new products through genetically enhanced tissues, applied topically, that produce elevated levels of natural wound healing and antimicrobial factors. Phase I development is underway in diabetic foot and venous leg ulcers, with other potential applications under consideration.
Source:
Advertisement
Related to this article
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
Florin Muraru, Gourav Pandey, and Richard Jaenisch explain where human sign-off belongs as multi-agent AI and document-parsing models reach GxP.
In this episode of Ask the Expert, Siegfried Schmitt, PhD, vice president, Technical at Parexel, and Susan J. Schniepp, distinguished fellow at Nelson Labs, discuss how companies should approach post-approval changes to their CMC regulatory filings.
The EC has approved AstraZeneca's Trixeo Aerosphere as the first single-inhaler triple-combination therapy for asthma in the EU, based on phase e data showing improved lung function and fewer severe exacerbations in patients uncontrolled on standard ICS/LABA treatment.
In this episode of Pharma Fundamentals, Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River, provides an introduction to the use of digital pathology in drug development.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Risk-Based Life Cycle Management of Master Production and Control Records to Strengthen Data Integrity and GMP Inspection Readiness Part 2: Practical Considerations for CGMP Documentation Systems
2
The FDA Finalizes Rule Recognizing Non-Animal Testing Methods, Building on Year-Long Reduction Push
3
PharmTech’s Weekly Roundup—September 25, 2026
4
CPHI Milan: USP Benchmarks Reshape Procurement Incentives
5